Pancreatic cancer is a very aggressive cancer type associated with one of the poorest
prognostics. Despite several clinical trials to combine different types of therapies, none of …

Background Microvascular invasion (MVI) has been proved to be poor prognostic factor in
many cancers. To date, only one study published highlights the relationship between this …

Objective: We aimed to determine if advances in neoadjuvant therapy affected recurrence
patterns and survival outcomes after pancreatectomy for pancreatic ductal adenocarcinoma …

Efficacy and safety of laparoscopic radical resection following neoadjuvant therapy for
pancreatic ductal adenocarcinoma: A retrospective study - PMC Back to Top Skip to main …

Background The clinical relevance of subdivision of non-metastatic pancreatic ductal
adenocarcinoma (PDAC) into locally advanced borderline resectable (LA-BR) and locally …

Locally advanced and borderline resectable pancreatic cancers are being increasingly
recognized as a result of significant improvements in imaging modalities. The main tools …

Undifferentiated/unclassified soft-tissue sarcomas (USTS) is recalcitrant neoplasms that is
usually treated with doxorubicin (DOX)-containing regimens as first-line therapy …

Introduction Neoadjuvant therapy (NAT) is an emerging strategy for operable pancreatic
ductal adenocarcinoma (PDAC). While NAT increases multimodal therapy completion, it …

The optimal regimens of neoadjuvant chemotherapy (NAC) and its biological and
physiological modification of the tumor microenvironment (TME) in patients with borderline …

Abstract Background The 2020 National Comprehensive Cancer Network guidelines
recommend neoadjuvant FOLFIRINOX or neoadjuvant gemcitabine plus nab‐paclitaxel (G …